I needed a dictionary for this great meeting. Words I am still not sure of include:
Netosis - #815 Plenary
Missense - #816 Plenary – I have been accused several times of missense
Autotaxin – #1796 – Is this a tax on the purchase of your car?!
Many non-pronounceable antibodies
Secukinumab – no, not a bad word, but a plenarly on Novartis’ secukinumab Monoclonal Antibody to Interleukin-17A in AS (#819)
A language degree and advanced medical knowledge may be needed to read the title of #2195: Eculizumab Treatment of Malignant Atrophic Papulosis (Köhlmeier-Degos Disease). Not sure how to pronounce eculizumab and I have never heard of Köhlmeier-Degos , but it works! Eculizumab is a monoclonal antibody that binds to complement protein C5 and prevents the conversion of C5 to C5a and C5b and was studied in antiphospholipid antibody syndrome (#13). Early results suggest it may be effective.
What about clazakizumab? I think you need a Vias to go this meeting if you are from there.
Krystexxa – is this a city near Corpus Christi, Texas? (AKA pegloticase)
Sirukumab – a foreign ambassador? (Sir Uku Mab, Actually anti-IL6 MAb #439)
Rituksimab (Abstract #509)
Brodalumab (Abstract #549) - anti-IL-17R monoclonal antibody trialed in Psoriasis and PsA
Tabalumab - human anti-BAFF monoclonal antibody (#677)
Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE; #719) - investigational monoclonal antibodies inhibiting type I IFN signaling
Are you a subsequent entry biologic (SEB) before you are approved by a Health Authority or after?
Dr. Janet Pope is Professor of Medicine at Western University and Division Head of Rheumatology. Dr. Pope's research interests include epidemiologic studies in scleroderma, classification criteria in systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.View Full Bio